Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;105(9):e474-479.
doi: 10.3324/haematol.2019.240762.

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Faouzi Djebbari  1 , Fotios Panitsas  2 , Toby A Eyre  3 , Catherine Prodger  3 , Fearn Davies  4 , Kieran Burton  3 , Akhil Khera  3 , Grant Vallance  3 , Sally Moore  3 , Jaimal Kothari  3 , Andy Peniket  3 , Karthik Ramasamy  3
Affiliations

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Faouzi Djebbari et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence curves of infections. (A) Cumulative incidence curves of all infections according to elevated lactate dehydrogenase (LDH) (Y vs. N): (63% vs. 32.3%, P=0.00046). (B) Cumulative incidence curves of ≥g3 infections according to elevated LDH (Y vs. N): (44.4% vs. 20.8%, P=0.00743). (C) Cumulative incidence curves of all infections according to chronic obstructive pulmonary disease (COPD) (Y vs. N): (90.9% vs. 30.3%, P=1.71x10-8). (D) Cumulative incidence curves of ≥g3 infections according to COPD (Y vs. N): (72.7% vs. 19.5%, P=1.79x10-5). (E) Cumulative incidence curves of all infections according to smoking (Y vs. N): (71.4% vs. 31.6%, P=7.32 x10-5). (F) Cumulative incidence curves of ≥g3 infections according to smoking (Y vs. N): (52.4% vs. 14%, P=0.000613).
Figure 2.
Figure 2.
Landmark overall survival analysis. (A) Landmark overall survival (OS) analysis according to (no infections vs. all infections): (44.7 vs. 23 months, P=0.0838). (B) Landmark OS analysis according to (no ≥g3 infections vs. ≥g3 infections): (43.8 vs. 17.7 months, P=0.0176).
See this image and copyright information in PMC

References

    1. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncology. 2005;23(36):9219-9226. - PubMed
    1. Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin M.A. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev. 2014;28(2):75-86. - PubMed
    1. Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program. 2017;(1):498-507. - PMC - PubMed
    1. Zweegman S, Palumbo A, Bringhen S, Sonneveld P. Age and aging in blood disorders: multiple myeloma. Haematologica. 2014; 99(7):1133-1137. - PMC - PubMed
    1. Offidani M, Corvatta L, Bringhen L, et al. Infection complications in 476 patients with newly diagnosed multiple myeloma treated with lenalidomide or bortezomib combinations. Blood. 2015;126(23): 5365.